Riverwater Partners LLC Has $502,000 Holdings in Iradimed Corporation (NASDAQ:IRMD)

Riverwater Partners LLC decreased its position in Iradimed Corporation (NASDAQ:IRMD) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,119 shares of the medical equipment provider’s stock after selling 506 shares during the quarter. Riverwater Partners LLC owned 0.08% of Iradimed worth $502,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its position in Iradimed by 73.8% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 8,925 shares of the medical equipment provider’s stock valued at $393,000 after buying an additional 3,791 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Iradimed in the first quarter worth $476,000. BNP Paribas Financial Markets grew its position in Iradimed by 139.3% in the first quarter. BNP Paribas Financial Markets now owns 17,088 shares of the medical equipment provider’s stock valued at $752,000 after purchasing an additional 9,948 shares in the last quarter. Swiss National Bank increased its stake in Iradimed by 8.7% in the 1st quarter. Swiss National Bank now owns 16,200 shares of the medical equipment provider’s stock valued at $713,000 after buying an additional 1,300 shares during the last quarter. Finally, Isthmus Partners LLC lifted its position in Iradimed by 880.8% during the 1st quarter. Isthmus Partners LLC now owns 71,905 shares of the medical equipment provider’s stock worth $3,163,000 after buying an additional 64,574 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm decreased their price objective on Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a report on Friday, August 2nd.

Iradimed Trading Down 0.9 %

NASDAQ IRMD opened at $50.49 on Thursday. Iradimed Corporation has a 12 month low of $38.53 and a 12 month high of $52.45. The stock has a 50 day moving average of $48.13 and a 200-day moving average of $45.10. The company has a market cap of $639.41 million, a PE ratio of 35.81 and a beta of 0.79.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.05. The company had revenue of $17.93 million during the quarter, compared to the consensus estimate of $17.70 million. Iradimed had a net margin of 26.83% and a return on equity of 24.71%. During the same quarter last year, the firm posted $0.33 EPS. As a group, sell-side analysts predict that Iradimed Corporation will post 1.41 EPS for the current fiscal year.

Iradimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Tuesday, August 20th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Tuesday, August 20th. This represents a $0.60 annualized dividend and a dividend yield of 1.19%. Iradimed’s dividend payout ratio is currently 42.55%.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.